Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide
Open Access
- 27 October 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 128 (1) , 18-28
Abstract
Inflammatory demyelinating neuropathies such as Guillain-Barré syndrome (GBS) and its animal model, experimental autoimmune neuritis (EAN), are typically acute monophasic diseases of the PNS that can leave affected individuals with permanent disability due primarily to axonal degeneration. The mechanisms underlying the degeneration are not understood, but we have previously shown in vitro and in vivo that axons can degenerate when exposed to the inflammatory mediator nitric oxide, and that axons can be protected by application of the sodium channel-blocking agent, flecainide. Here we examine whether flecainide administration can similarly reduce axonal degeneration in the periphery in animals with EAN. EAN was induced in Lewis rats (n = 116, in three independent trials), and rats received either flecainide (Flec) (30 mg/kg/day) or vehicle (Veh) from the onset of disease expression. Flecainide administration significantly reduced the mean (SD) scores for neurological deficit at both the peak of disease (Flec: 5.7 (2.7), Veh: 8.0 (3.6), P < 0.001) and at the termination of the trials 25–29 days post-inoculation (Flec: 2.2 (2.4), Veh: 4.2 (4.2), P < 0.001). Histological examination of the tibial nerve of EAN animals revealed that flecainide provided significant protection against axonal degeneration so that 80.0% of the normal number of axons survived in flecainide-treated rats compared with 62.8% in vehicle-treated rats (P < 0.01). These findings may indicate a novel avenue for axonal protection in GBS and other inflammatory demyelinating neuropathies.Keywords
This publication has 73 references indexed in Scilit:
- Axonal protection using flecainide in experimental autoimmune encephalomyelitisAnnals of Neurology, 2004
- Neurophysiological changes in demyelinating and axonal forms of acute experimental autoimmune neuritis in the Lewis ratMuscle & Nerve, 2003
- Blockers of sodium and calcium entry protect axons from nitric oxide‐mediated degenerationAnnals of Neurology, 2002
- Disruption and reorganization of sodium channels in experimental allergic neuritisMuscle & Nerve, 1998
- Mechanism of Calcium Entry during Axon Injury and DegenerationToxicology and Applied Pharmacology, 1997
- Inflammatory infiltrates in sural nerve biopsies in Guillain-Barr syndrome and chronic inflammatory demyelinating neuropathyMuscle & Nerve, 1996
- Sodium-selective channels in membranes of rat macrophagesThe Journal of Membrane Biology, 1994
- Response of the axon and barrier endothelium to experimental allergic neuritis induced by autoreactive T cell linesActa Neuropathologica, 1991
- T-Cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barr syndromeAnnals of Neurology, 1990
- Flecainide: A new antiarrhythmic drugClinical Cardiology, 1986